iRhythm Technologies, Inc (IRTC)
iRhythm Technologies, Inc. is a healthcare company specializing in the development and commercialization of wearable biosensing devices and cloud-based data analysis tools for cardiac monitoring. Its flagship product, the Zio service, provides ambulatory ECG monitoring to detect arrhythmias, enabling improved diagnosis and management of cardiovascular conditions. Founded in 2006 and headquartered in San Francisco, iRhythm aims to enhance patient care through innovative digital health solutions.
Company News
A clinical trial showed home-based long-term continuous ECG monitoring using Zio device increased atrial fibrillation detection and reduced time to diagnosis in patients aged 65+ with moderate to high stroke risk.
iRhythm Technologies reported strong Q1 2025 results, with revenue growing 20.3% year-over-year driven by increased demand for its Zio services. The company's gross margin also improved, and it provided an upbeat guidance for fiscal 2025. Analysts have turned bullish on the stock, with Wells Fargo upgrading it to Overweight.
An executive at iRhythm Technologies sold $148,332 worth of the company's stock to cover tax obligations related to the vesting of Restricted Stock Units. The executive still retains a substantial holding of 27,255 shares in the company.
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.